New Developments in 340B Contract Pharmacy Lawsuits
Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies. The government asked AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics to provide an update by next Tuesday, June 1, on their plans for resuming 340B pricing when covered entities contract with outside pharmacies.